Literature DB >> 34905500

Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas.

Antoine Tabarin1, Magalie Haissaguerre1, Hélène Lassole2, Arnaud Jannin3, Anne-Cecile Paepegaey4, Olivier Chabre5, Jacques Young6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34905500     DOI： 10.1530/EJE-21-1008

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


× No keyword cloud information.
  2 in total

1.  Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.

Authors:  Mario Detomas; Barbara Altieri; Timo Deutschbein; Martin Fassnacht; Ulrich Dischinger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-13       Impact factor: 6.055

Review 2.  Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.

Authors:  Maria Fleseriu; Beverly M K Biller
Journal:  Pituitary       Date:  2022-08-24       Impact factor: 3.599
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.